AbbVie (NYSE: ABBV) has secured European Commission approval for Rinvoq in children as young as two with active polyarticular juvenile idiopathic arthritis, extending one of the pharmaceutical company’s fastest-growing medicines into a pediatric population where persistent inflammation can cause irreversible joint damage. The approval covers patients who have responded inadequately to, or cannot tolerate, one or more disease-modifying anti-rheumatic drugs, and allows upadacitinib to be used either alone or with methotrexate. AbbVie also gained approval for a new weight-based 1 mg/mL oral solution, allowing younger children who cannot swallow tablets to receive the JAK inhibitor.
The September 22 decision adds an eleventh European Union indication to the Rinvoq franchise and gives AbbVie another opportunity to extend its immunology business across age groups rather than relying solely on adult rheumatoid arthritis, inflammatory bowel disease and dermatology. The regulatory decision was supported by the open-label Phase 1 SELECT-YOUTH study involving 122 children, together with efficacy information from adult rheumatoid arthritis patients. By week 48, 79.5% of children in SELECT-YOUTH achieved at least a 70% improvement in pediatric American College of Rheumatology disease-activity criteria, while 43.4% reached clinical remission according to the JADAS27-CRP measure.
The commercial significance extends beyond the relatively specialized pediatric indication. Rinvoq generated $2.525 billion in worldwide second-quarter 2026 revenue, increasing 24.5% from a year earlier, and has become one of the two medicines carrying AbbVie through the erosion of Humira. Together with Skyrizi, Rinvoq is transforming AbbVie’s immunology business from dependence on one historic blockbuster into a multi-indication platform capable of expanding across rheumatology, gastroenterology and dermatology.
How effective was Rinvoq in children with polyarticular juvenile idiopathic arthritis?
SELECT-YOUTH enrolled children between two and under 18 years old with polyarticular-course juvenile idiopathic arthritis and evaluated pharmacokinetics, efficacy, safety and tolerability. All patients received either a 15-milligram-equivalent dose through extended-release tablets or a weight-based oral solution, with the formulation determined partly by body weight and whether the child could swallow tablets. Because the study was single-arm and open label, it did not include a randomized placebo or active-comparator group, an important limitation when interpreting the magnitude of the response.
Nevertheless, the response rates increased substantially as treatment continued. At week 12, 66.4% of patients had achieved an ACR pediatric 70 response, indicating at least 70% improvement across the relevant disease measures, and that figure increased to 79.5% at week 48. Clinical remission increased from 23% at week 12 to 43.4% at week 48, while measures of functional ability and pain also improved progressively through the study.
Functional ability, assessed using the Childhood Health Assessment Questionnaire, improved by an average 0.46 points from baseline at week 12 and 0.64 points by week 48. Pain scores fell by 26.2 points at week 12 and 30.8 points at week 48 among patients with observed data. For families dealing with a chronic childhood inflammatory disease, these endpoints matter because treatment success involves more than lowering laboratory inflammation: children need to regain mobility, participate in school and physical activity, and avoid the structural joint damage that can follow years of inadequately controlled disease.
Why does an oral solution matter in pediatric arthritis?
Drug formulation can become a surprisingly important commercial differentiator in pediatrics. A therapy approved only as a large tablet may technically have a pediatric indication while remaining impractical for very young children, and injectable biologics introduce another layer of administration burden for families managing a chronic disease.
AbbVie’s newly approved Rinvoq oral solution allows dosing to be adjusted according to body weight for children who cannot use the extended-release tablet. That gives the company a route into the youngest eligible age group rather than restricting the drug primarily to adolescents capable of swallowing solid medication.
The advantage should not be overstated because oral competition already exists. Pfizer’s Xeljanz, or tofacitinib, is approved in the European Union for active polyarticular juvenile idiopathic arthritis in children from two years of age and is available as both tablets and an oral solution. Meanwhile, injectable treatments including adalimumab products such as Humira and its biosimilars are also approved from age two in appropriate pediatric patients.
Rinvoq therefore enters an established treatment market rather than creating one. Its commercial opportunity will depend on efficacy, safety, physician experience, reimbursement and how pediatric rheumatologists position JAK inhibition relative to methotrexate, TNF inhibitors and other targeted therapies after inadequate response to conventional treatment.
How large is the juvenile idiopathic arthritis population AbbVie is targeting?
Juvenile idiopathic arthritis is the most common chronic rheumatic disease in children, and AbbVie estimates that approximately 126,000 children across Europe are affected by JIA overall. Polyarticular disease is characterized by inflammation involving at least five joints, potentially including the hands, feet, knees, hips and ankles, with disease persisting for at least six weeks. Persistent activity can cause pain, impaired mobility and progressive joint damage, while symptoms or recurrent flares can continue into adulthood.
Not all of those 126,000 children are eligible for Rinvoq because juvenile idiopathic arthritis encompasses several subtypes and the European label specifically covers active polyarticular rheumatoid factor-positive or rheumatoid factor-negative disease and extended oligoarticular disease after inadequate response or intolerance to at least one DMARD. The immediately addressable population is therefore much smaller than the headline European JIA figure.
Even so, pediatric chronic disease has commercial value beyond patient numbers because treatment can continue over long periods when a medicine maintains disease control. Successful pediatric expansion also embeds the product earlier in the treatment ecosystem and strengthens AbbVie’s relationships with rheumatologists who already use Rinvoq across adult inflammatory diseases.
Where does Rinvoq fit against biologics and other JAK inhibitors?
Methotrexate remains a foundational disease-modifying therapy in polyarticular juvenile idiopathic arthritis, while patients with persistent moderate or severe disease may move to targeted treatments such as TNF inhibitors, interleukin-6 inhibitors or JAK inhibitors. Treatment recommendations generally recognize biologic therapies and targeted agents when conventional DMARD treatment is inadequate, although the strength of evidence differs between drug classes and geographic guidelines.
Adalimumab provides one important benchmark. The European Medicines Agency notes that Humira is approved for polyarticular juvenile idiopathic arthritis from age two, with clinical studies showing fewer arthritis flares among treated children than placebo recipients. Numerous adalimumab biosimilars now compete in Europe, which can make TNF inhibition economically attractive for healthcare systems.
Pfizer’s Xeljanz presents a more direct mechanistic comparison because it is another oral JAK inhibitor approved for active polyarticular juvenile idiopathic arthritis from age two after inadequate response to DMARD therapy. Rinvoq will consequently need to establish a place in a market where physicians already have oral and injectable targeted options rather than relying solely on the convenience of avoiding injections.
AbbVie’s advantage is familiarity across inflammatory diseases. Rinvoq already has European indications spanning rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, giant cell arteritis, alopecia areata, vitiligo and now polyarticular juvenile idiopathic arthritis. That breadth creates substantial physician experience with the molecule, although experience in adults cannot substitute for long-term pediatric safety evidence.
What does SELECT-YOUTH show about Rinvoq safety in children?
AbbVie reported no new safety risks during SELECT-YOUTH and said the pediatric safety profile was consistent with the established Rinvoq profile. No major cardiovascular events, thrombotic events, malignancies or deaths occurred during the reported study period, and investigators observed no adverse impact on growth or development. Serious adverse events occurred at a rate of 10.2 events per 100 patient-years, while adverse events leading to treatment discontinuation occurred at 2.7 per 100 patient-years.
Those findings are reassuring but need to be placed in the context of the broader JAK-inhibitor safety framework. Rinvoq carries warnings involving serious infections, malignancy, major cardiovascular events and venous thromboembolism, with European prescribing information requiring additional caution in patients with relevant risk factors. Serious infections remain among the most important adverse reactions associated with treatment.
Many of the cardiovascular and malignancy warnings derive partly from safety findings observed with another JAK inhibitor in older rheumatoid arthritis patients with cardiovascular risk factors, a population very different from young children with JIA. It would therefore be inappropriate to assume that the same absolute risk applies to pediatric patients. Conversely, the absence of those events in a 122-patient study cannot establish their absence over decades of potential treatment, making long-term pharmacovigilance important as use expands.
Why is another Rinvoq indication financially important for AbbVie?
AbbVie’s transformation after Humira biosimilar entry has become increasingly visible in its financial results. Second-quarter 2026 total revenue rose 10.2% to $16.99 billion, while immunology revenue increased 15.1% to $8.786 billion. Skyrizi generated $5.505 billion and Rinvoq contributed $2.525 billion, with both products growing roughly 24% year over year, while Humira revenue fell 35.9% to $756 million.
The mathematics explain AbbVie’s aggressive indication-expansion strategy. Every additional Rinvoq population increases the potential return from a medicine whose discovery, manufacturing and commercial infrastructure are already established. Pediatric arthritis alone will not materially transform a franchise already running above $10 billion on an annualized quarterly basis, but multiple incremental indications can compound into substantial long-term revenue.
The European decision also reinforces AbbVie’s strategy of turning Rinvoq into a platform drug rather than a single-disease successor to Humira. Continued Phase 3 development includes hidradenitis suppurativa, Takayasu arteritis and systemic lupus erythematosus, alongside additional pediatric programs in systemic juvenile idiopathic arthritis, atopic dermatitis, ulcerative colitis and Crohn’s disease.
What is the latest AbbVie stock sentiment after the approval?
AbbVie shares ended September 22 around $265.5, rising modestly during the session and remaining near the upper end of their recent trading range. The stock had climbed from roughly $251 on September 9 to above $265 by September 22, indicating improving near-term sentiment, although the pediatric Rinvoq approval should not be treated as the sole driver of that move.
Investors are evaluating a much larger set of variables, including Skyrizi and Rinvoq growth, Humira erosion, AbbVie’s neuroscience portfolio, oncology pipeline, acquisitions and future immunology launches. The latest Rinvoq approval is therefore more important as evidence of franchise durability than as a near-term earnings catalyst.
That distinction captures the strategic value of the European decision. AbbVie does not need polyarticular juvenile idiopathic arthritis to become another multibillion-dollar market. It needs Rinvoq to keep expanding into clinically relevant populations while maintaining enough efficacy, safety and formulation flexibility to support continued double-digit franchise growth.
For families, the new European approval creates another oral targeted option after conventional disease-modifying therapy is insufficient. For AbbVie, it turns a medicine already generating more than $2.5 billion every quarter into an even broader immunology platform, while the new pediatric oral solution helps ensure the franchise can reach patients from age two rather than stopping at the adult rheumatology clinic.
